Climb Bio, Inc. - Common Stock, par value $0.0001 per share (CLYM) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
CLYM on Nasdaq
Shares outstanding
54,403,891
Price per share
$5.03
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
6,585,870
Total reported value
$26,359,434
% of total 13F portfolios
0%
Share change
-1,305,977
Value change
-$3,133,691
Number of holders
29
Price from insider filings
$5.03
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Climb Bio, Inc. - Common Stock, par value $0.0001 per share (CLYM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 33% $36,086,101 17,953,284 RA Capital Management, L.P. 11 Dec 2025
Pontifax Management 4 G.P. (2015) Ltd. 7.7% $12,911,822 5,206,380 Pontifax VI G.P. L.P. 27 Jun 2024

As of 31 Dec 2025, 29 institutional investors reported holding 6,585,870 shares of Climb Bio, Inc. - Common Stock, par value $0.0001 per share (CLYM). This represents 12% of the company’s total 54,403,891 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Climb Bio, Inc. - Common Stock, par value $0.0001 per share (CLYM) together control 12% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 2.5% 1,340,504 +1.9% 0% $5,362,016
Affinity Asset Advisors, LLC 2.4% 1,300,000 0% 0.37% $5,200,000
Peapod Lane Capital LLC 1% 565,992 +0.73% 1.9% $2,263,968
NAN FUNG TRINITY (HK) LTD 0.85% 463,654 0% 0.15% $1,854,616
BlackRock, Inc. 0.72% 389,309 -47% 0% $1,557,236
RENAISSANCE TECHNOLOGIES LLC 0.59% 320,600 -40% 0% $1,282,400
GEODE CAPITAL MANAGEMENT, LLC 0.57% 310,756 -0.31% 0% $1,243,615
MARSHALL WACE, LLP 0.56% 304,015 +32% 0% $1,216,060
TD Asset Management Inc 0.45% 246,200 +175% 0% $984,800
GOLDMAN SACHS GROUP INC 0.41% 224,883 +205% 0% $899,532
JANE STREET GROUP, LLC 0.34% 187,403 +135% 0% $749,612
MORGAN STANLEY 0.27% 148,538 +72% 0% $594,152
MANUFACTURERS LIFE INSURANCE COMPANY, THE 0.26% 140,617 +261% 0% $566,650
STATE STREET CORP 0.24% 128,900 +25% 0% $515,600
ArchPoint Investors 0.22% 121,400 0.12% $485,600
OMERS ADMINISTRATION Corp 0.16% 85,466 0% $341,864
UBS Group AG 0.13% 71,323 -82% 0% $285,292
LPL Financial LLC 0.11% 62,000 +1.6% 0% $248,000
BARCLAYS PLC 0.11% 61,853 +150% 0% $247,412
Hudson Bay Capital Management LP 0.09% 48,736 0% $194,944
CITIZENS FINANCIAL GROUP INC/RI 0.05% 28,168 -39% 0% $112,672
Vanguard Personalized Indexing Management, LLC 0.02% 11,127 -24% 0% $44,508
Chicago Partners Investment Group LLC 0.02% 10,962 +6.1% 0% $55,029
CITIGROUP INC 0.02% 10,331 -97% 0% $41,324
HARBOUR INVESTMENTS, INC. 0% 2,000 0% 0% $8,000

Institutional Holders of Climb Bio, Inc. - Common Stock, par value $0.0001 per share (CLYM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 6,585,870 $26,359,434 -$3,133,691 $4.00 29
2025 Q3 44,576,107 $89,598,934 -$10,311,694 $2.01 66
2025 Q2 49,893,947 $61,871,600 -$2,503,034 $1.24 68
2025 Q1 51,939,064 $63,368,269 -$8,741,696 $1.22 76
2024 Q4 55,706,408 $100,272,719 -$19,354,214 $1.80 78
2024 Q3 54,655,767 $278,130,509 +$14,600,273 $5.09 69
2024 Q2 49,901,732 $354,801,793 +$245,093,722 $7.11 46
2024 Q1 16,855,387 $46,194,788 +$5,051 $2.74 20
2023 Q4 16,853,724 $45,505,627 +$348,407 $2.70 22
2023 Q3 16,728,590 $43,997,383 -$6,828 $2.63 22
2023 Q2 16,730,361 $46,844,345 +$79,298 $2.80 21
2023 Q1 16,702,070 $48,434,001 +$194,589 $2.90 19
2022 Q4 16,628,134 $61,000,699 +$90,854 $3.67 20
2022 Q3 14,807,225 $47,821,510 -$982,037 $3.23 20
2022 Q2 15,127,218 $45,689,000 -$21,553,504 $3.02 22
2022 Q1 17,488,772 $146,733,000 +$663,723 $8.39 40
2021 Q4 17,373,074 $181,720,000 +$142,325 $10.46 34
2021 Q3 17,279,112 $310,677,000 +$310,677,000 $17.98 31